Dark

Check out our Dark Pool Levels

AYLA
Ayala Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Jan 18, 2023

0.5036USD+5.843%(+0.0278)137,797

Pre-market

0.00USD-100.000%(-0.48)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 6, 2022

08:28AM EST Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect GlobeNewswire Inc

Jan 4, 2022

08:27AM EST Ayala Pharma Offers Key Business Objectives For 2022 Benzinga

08:00AM EST Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced its key objectives for 2022. GlobeNewswire Inc

Dec 20, 2021

11:58AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021 Benzinga

09:31AM EST Maxim Group Initiates Coverage On Ayala Pharmaceuticals with Buy Rating, Announces Price Target of $22 Benzinga

06:24AM EST HC Wainwright & Co. Initiates Coverage On Ayala Pharmaceuticals with Buy Rating, Announces Price Target of $18 Benzinga

Nov 30, 2021

04:51PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 Benzinga

04:43PM EST Jefferies Upgrades Ayala Pharmaceuticals to Buy, Raises Price Target to $17 Benzinga

Nov 15, 2021

11:04AM EST Ayala Pharmaceuticals Q3 EPS $(0.68) Down From $(0.59) YoY, Sales $625.00K Down From $658.00K YoY Benzinga

08:00AM EST - Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 GlobeNewswire Inc

Nov 10, 2021

08:00AM EST Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET). GlobeNewswire Inc

Sep 23, 2021

08:36AM EDT Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity Of Co's Gamma Secretase Inhibitor AL101 In Desmoid Tumors Benzinga

08:30AM EDT Ayala Pharmaceuticals Announces Publication Highlighting Clinical GlobeNewswire Inc

Sep 16, 2021

08:07AM EDT Ayala Pharmaceuticals Highlights Presentation Of Preliminary Clinical Data From Ongoing Phase 2 ACCURACY Trial And Announces Pre-Clinical Proof Of Concept Data For Enhanced Activity Of AL101 In Combination Aith Approved Cancer Therapies In ACC Benzinga

08:00AM EDT - Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 GlobeNewswire Inc

Sep 2, 2021

08:00AM EDT Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September: GlobeNewswire Inc

Sep 1, 2021

08:03AM EDT Ayala Pharma Highlights Upcoming ePoster Presentations At European Society For Medical Oncology Congress Sept. 16-21, 2021 Benzinga

08:00AM EDT Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase GlobeNewswire Inc

Aug 17, 2021

07:19AM EDT Oppenheimer Maintains Outperform on Ayala Pharmaceuticals, Lowers Price Target to $25 Benzinga

Aug 13, 2021

08:49AM EDT Recap: Ayala Pharmaceuticals Q2 Earnings Benzinga

08:05AM EDT Ayala Pharmaceuticals Q2 EPS $(0.75) Down From $(0.74) YoY Benzinga

08:00AM EDT - Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors GlobeNewswire Inc

Jul 13, 2021

10:15AM EDT Ayala's Stock Surges After Ladenburg Initiates Coverage With Price Target Of $29 Benzinga

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

08:39AM EDT Ladenburg Thalmann Initiates Coverage On Ayala Pharmaceuticals with Buy Rating, Announces Price Target of $29 Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 6, 2021

09:02AM EDT Ayala Pharmaceuticals Says To Present At Ladenburg Thalmann Healthcare Conference Benzinga

09:00AM EDT Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET. GlobeNewswire Inc

Jun 4, 2021

04:10PM EDT Ayala Pharma Files For ~2.25M Share Common Stock Offering Via Selling Shareholders, Separate S-3 Filing For $200M Mixed Securities Shelf Offering Benzinga

May 27, 2021

09:01AM EDT Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

May 14, 2021

08:16AM EDT Ayala Pharmaceuticals Q1 EPS $(0.74) Up From $(1.32) YoY Benzinga

08:16AM EDT - First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis Anti-BCMA Agent for the Treatment of Multiple Myeloma - GlobeNewswire Inc

May 8, 2021

03:19AM EDT Shares of Ayala Pharmaceuticals Inc. (AYLA) are off 65% from their 52-week high of $28.68, recorded in February of this year, and trade around $10. RTTNews

Apr 21, 2021

08:37AM EDT Ayala Says First Patient Dosed In Phase 1 Clinical Trial Of AL102 Plus BCMA Targeting Agent, WVT078 RTTNews

08:03AM EDT Ayala Pharmaceuticals Announces First Patient Dosed In Phase 1 Clinical Trial Of AL102 In Combination With BCMA Targeting Agent, WVT078, In Patients With Relapsed/Refractory Multiple Myeloma Benzinga

08:00AM EDT Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 GlobeNewswire Inc

Mar 25, 2021

08:07AM EDT Ayala Pharmaceuticals Q4 EPS $(0.73), Sales $1.00M Benzinga

08:00AM EDT - Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 GlobeNewswire Inc

Mar 2, 2021

08:00AM EST Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will present at three upcoming virtual investor conferences: GlobeNewswire Inc

Feb 19, 2021

10:50AM EST Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors Benzinga

09:30AM EST Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Jan 28, 2021

09:15AM EST Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 GlobeNewswire Inc

Jan 13, 2021

04:01PM EST Ayala Pharmaceuticals to Present at Noble Capital Markets 17th GlobeNewswire Inc

Jan 5, 2021

08:00AM EST Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright GlobeNewswire Inc

Jan 4, 2021

08:28AM EST Ayala Announces Completion Of End-of-Phase 1 Meeting With FDA On AL102 RTTNews

08:03AM EST Ayala Pharmaceuticals To Accelerate Development Of AL102 For Treatment Of Desmoid Tumors In Pivotal Phase 2/3 Study Benzinga

08:00AM EST - FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - GlobeNewswire Inc

Dec 7, 2020

07:17AM EST Roth Capital Initiates Coverage On Ayala Pharmaceuticals with Buy Rating, Announces Price Target of $20 Benzinga

Dec 2, 2020

11:23AM EST Noble Capital Markets Initiates Coverage On Ayala Pharmaceuticals with Outperform Rating, Announces Price Target of $29 Benzinga

Nov 17, 2020

08:02AM EST Ayala Pharmaceuticals Late Monday Reported Q3 EPS $(0.59), Sales $658.00K Benzinga

08:01AM EST - Presented New Positive Interim Data from 4mg Cohort of Phase 2 ACCURACY Study of AL101 for the Treatment of R/M ACC at European Society for Medical Oncology2020- GlobeNewswire Inc

Sep 18, 2020

07:02AM EDT Ayala Pharma To Present Interim Data From Phase 2 ACCURACY Trial Of AL1010 For Treatment OF Recurrent/Metastatic Adenoid Cystic Carcinoma With Notch Activating Mutations At European Society for Medical Oncology Congress Sept. 18 Benzinga

07:00AM EDT Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate GlobeNewswire Inc

Sep 14, 2020

08:01AM EDT Ayala Pharmaceuticals to Host Virtual KOL Event Reviewing Interim GlobeNewswire Inc

Sep 8, 2020

08:01AM EDT Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Ayala management will present at two upcoming investor conferences: GlobeNewswire Inc

Aug 20, 2020

08:01AM EDT Ayala Pharmaceuticals Announces the Appointment of Vered GlobeNewswire Inc

Aug 13, 2020

08:18AM EDT Ayla Pharmaceuticals EPS $(0.74) Vs $(0.76) YoY Benzinga

08:01AM EDT New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 GlobeNewswire Inc

Jul 27, 2020

08:18AM EDT Ayala Pharma To Present Updated Data From Phase 2 ACCURACY Trial Of AL101 For R/M Adenoid Cystic Carcinoma At ESMO RTTNews

08:01AM EDT Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 GlobeNewswire Inc

Share